Related Experiment Video
Updated: May 6, 2026
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
Christopher J Lord1, Alan Ashworth
1The Breakthrough Breast Cancer Research Centre and Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, UK.
Abstract:
Synthetic lethality provides a potential mechanistic framework for the therapeutic targeting of genetic and functional deficiencies in cancers and is now being explored widely. The first clinical exemplification of synthetic lethality in cancer has been the exploitation of inhibitors of poly-(ADP-ribose) polymerase (PARP) for the treatment of cancers with defects in the BRCA1 or BRCA2 tumor suppressor proteins, which are involved in the repair of DNA damage. Although this approach has shown promise, multiple potential resistance mechanisms have been identified. In this Perspective, we discuss these mechanisms and their relevance to the development of selective therapies for BRCA-deficient cancers.
Insights
Synthetic lethality, a cancer therapy approach, is being widely explored. Poly-(ADP-ribose) polymerase (PARP) inhibitors show promise for BRCA-deficient cancers but face resistance mechanisms.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Synthetic lethality offers a therapeutic strategy for targeting cancer-specific genetic vulnerabilities.
- Poly-(ADP-ribose) polymerase (PARP) inhibitors represent the first clinical application of synthetic lethality in cancer treatment.
- This approach is particularly relevant for cancers with defects in BRCA1 or BRCA2 tumor suppressor genes, crucial for DNA damage repair.
Purpose of the Study:
- To discuss identified resistance mechanisms against PARP inhibitors in BRCA-deficient cancers.
- To explore the relevance of these resistance mechanisms for developing future selective therapies.
Main Methods:
- Literature review and analysis of existing research on synthetic lethality and PARP inhibitors.
- Discussion of known and potential resistance pathways.
Main Results:
- Multiple mechanisms of resistance to PARP inhibitors in BRCA-deficient cancers have been identified.
- Understanding these resistance mechanisms is crucial for optimizing therapeutic strategies.
Conclusions:
- Despite promising results, acquired resistance limits the long-term efficacy of PARP inhibitors.
- Further research into resistance mechanisms is essential for developing more effective and durable treatments for BRCA-deficient cancers.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
09:24Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
Published on: August 12, 2015
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:53Adaptive Mechanisms in Cancer Cells
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...